13 Lung Cancer Clinical Trials in Little Rock, AR (2026)

Q: How do I join a clinical trial in Little Rock?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Little Rock research site will contact you.

Recruiting Lung Cancer Studies in Little Rock

NCT05899608Recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non...

Little Rock, ARPHASE31,600 participantsSummit Therapeutics

View Study Details

NCT06632327Recruiting

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell ...

Little Rock, ARPHASE31,100 participantsAlliance for Clinical Trials in Oncology

View Study Details

NCT06422143Recruiting

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; M...

Little Rock, ARPHASE3851 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06312137Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypo...

Little Rock, ARPHASE3780 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06357533Recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy ...

Little Rock, ARPHASE3675 participantsAstraZeneca

View Study Details

NCT07472517Recruiting

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carbopla...

Little Rock, ARPHASE3670 participantsBoehringer Ingelheim

View Study Details

NCT05061550Recruiting

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Vo...

Little Rock, ARPHASE2630 participantsAstraZeneca

View Study Details

NCT05624996Recruiting

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by ...

Little Rock, ARPHASE3474 participantsNRG Oncology

View Study Details

NCT06568939Recruiting

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues...

Little Rock, ARPHASE2150 participantsAbbVie

View Study Details

NCT06116682Recruiting

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a ...

Little Rock, ARPHASE288 participantsSWOG Cancer Research Network

View Study Details

NCT05642572Recruiting

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread fr...

Little Rock, ARPHASE266 participantsSWOG Cancer Research Network

View Study Details

NCT06031688Recruiting

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first s...

Little Rock, ARPHASE256 participantsSWOG Cancer Research Network

View Study Details

NCT03191149Recruiting

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period o...

Little Rock, ARPHASE246 participantsNational Cancer Institute (NCI)

View Study Details

About Lung Cancer Clinical Trials in Little Rock

Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.

There are currently 13 lung cancer clinical trials recruiting participants in Little Rock, AR. These studies are seeking a combined 7,186 participants. Research is being sponsored by Summit Therapeutics, Alliance for Clinical Trials in Oncology, Merck Sharp & Dohme LLC and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lung Cancer Clinical Trials in Little Rock — FAQ

Are there lung cancer clinical trials in Little Rock?

Yes, there are 13 lung cancer clinical trials currently recruiting in Little Rock, AR. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Little Rock?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Little Rock research site will contact you about next steps.

Are clinical trials in Little Rock free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Little Rock studies also compensate for your time and travel.

What lung cancer treatments are being tested?

The 13 active trials in Little Rock are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.

Data updated July 17, 2026 from ClinicalTrials.gov